Table 1.
The basic clinical characteristics of patients in this study
| Variables | Range |
|---|---|
| Male: Female | 54 (17.3%): 258 (82.7%) |
| Age (years) | 45.07 ± 12.79 |
| Duration of Graves’ hyperthyroidism (months) | 6 (1, 376) |
| Thyroid weight (g) | 52.21 (19.12, 239.00) |
| ATD therapy history (Male: Female) | 42 (77.8%): 205 (80.7%) |
| Propyltiouracil (Male: Female) | 5 (11.9%): 26 (12.7%) |
| Methimazole (Male: Female) | 37 (88.1%): 179 (87.3%) |
| FT3 (pmol/L) | 22.08 (4.35, 36.70) |
| FT4 (pmol/L) | 51.68 (3.51, 154.80) |
| TSH (uIU/mL) | 0.005 (0.001, 0.250) |
| TPOAb (IU/mL) | 1300 (23.30, 1300.00) |
| TRAb (IU/mL) | 12.72 (0.30, 40.00) |
| 2-h RAIU | 37.25 (7.80, 83.69) |
| 6-h RAIU | 66.24 (14.40, 95.62) |
| 24-h RAIU | 72.52 (27.29, 99.90) |
| 6/24-h uptake ratio | 92.07 (49.48, 126.70) |
| Dose of RAI (mCi) | 8.81 ± 2.90 |
FT3 Free triiodothyronine; FT4 Free thyroxine; TSH Thyrotropin; TPOAb Thyroperoxidase antibody; TRAb Thyrotropin receptor antibody; RAIU Radioactive iodine uptake